(Q24243168)

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Omega-3 fatty acids in bipolar disorder: clinical and research considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Effect of high doses of essential fatty acids on the postviral fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Cross-national comparisons of seafood consumption and rates of bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Importance of the Ratio of Omega-6/Omega-3 Essential Fatty Acids: Evolutionary Aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

A combination of hypothalamic phospholipid liposomes with trazodone for treatment of depression. An open controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Phospholipid liposomes in depression: a double-blind study versus placebo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Lecithin in mania: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Relation of serum valproate concentration to response in mania

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

A Double-Blind, Placebo-Controlled Study of the Omega-3 Fatty Acid Docosahexaenoic Acid in the Treatment of Major Depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005169.PUB2

7 January 2021

10.1002/14651858.CD005169.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18425912

1 reference

Consolidated OpenCitations Corpus – April 2017